Cognision Secures $100K Grant Funding

Cognision, a developer of neurocognitive assessment technology, has secured $100,000 in new investment capital from investors.

The company is known for the COGNISION® System, an FDA-cleared, cloud-powered EEG/ERP system designed for neurocognitive biomarkers and assessment.

This system empowers clinicians to effectively evaluate patients with conditions such as dementia, concussion/mTBI, and other neurocognitive disorders by combining scientific principles, innovation, and data analysis.

The COGNISION® system has been implemented in multiple clinical trials, playing a role in advancing the use of precision EEG/ERP biomarkers in central nervous system (CNS) drug development.

Its integrated platform, COGNISION360™, facilitates neurobiomarker acquisition, processing, and analysis in CNS clinical trials.

This comprehensive platform brings together various data streams, including electroencephalography (EEG), event-related potentials (ERP), polysomnography (PSG), eye tracking, wearable sensors, cognitive assessments, and electronic clinical outcome assessments (eCOA, ePRO, and eObsRO).

This funding round is significant for Cognision as it provides capital to support the company's strategic growth initiatives.

The investment will be directed towards further developing its proprietary technology, enhancing the capabilities of the COGNISION360™ platform, and expanding its market reach within the clinical and research sectors.

The capital is expected to enable Cognision to continue its work in advancing neurocognitive assessment tools.

As a founding member of the EEG/ERP Biomarker Qualification Consortium, Cognision is positioned to contribute to industry standards and innovation.

With this new funding, the company aims to solidify its role in providing advanced solutions for neurological health.

Cognision plans to continue its efforts in making precision EEG/ERP biomarkers more accessible and integrated into both clinical practice and drug development pipelines, ultimately supporting improved patient outcomes and therapeutic advancements.